Drug Profile
Research programme: anti-cancer immunotoxins - InNexus Biotechnology/National Cancer Institute
Alternative Names: DXL™; Transmab™Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA)
- Developer InNexus Biotechnology; National Cancer Institute (USA)
- Class Immunotoxins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 28 May 2010 Preclinical trials in Cancer in USA (Parenteral)